Spero Therapeutics (SPRO) Non Operating Income (2016 - 2026)
Spero Therapeutics (SPRO) reported Non Operating Income of -$1000.0 for Q1 2026, down 100.12% on a YoY basis from $865000.0 in Q1 2025, and up 99.95% quarter-over-quarter from -$2.1 million in Q4 2025.
Spero Therapeutics (SPRO) Non Operating Income (2016 - 2026) Analysis & Trends
Spero Therapeutics has reported Non Operating Income for 11 years, with the latest figure at -$1000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 100.12% year-over-year to -$1000.0; the trailing twelve-month figure through Mar 2026 stood at -$859000.0 (up 45.29% YoY), and the FY2025 full-year result was $7000.0, down 88.33% from the prior year.
- Non Operating Income for Q1 2026 stood at -$1000.0, up from -$2.1 million in the prior quarter.
- The five-year high for Non Operating Income was $1.2 million in Q2 2024, with the low at -$3.6 million in Q4 2024.
- Historically, Non Operating Income has averaged -$170470.6 across 5 years, with a median of -$2000.0 in 2023.
- Annual changes were most pronounced in 2022 — Non Operating Income tumbled 8573.33% — and 2023, when it soared 11722.22%.
- Spero Therapeutics' Non Operating Income stood at -$9000.0 in 2022, then soared by 11722.22% to $1.0 million in 2023, then tumbled by 444.93% to -$3.6 million in 2024, then soared by 40.8% to -$2.1 million in 2025, then jumped by 99.95% to -$1000.0 in 2026.
- The last three Non Operating Income figures came in at -$1000.0 (Q1 2026), -$2.1 million (Q4 2025), and $534000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Spero Therapeutics | 129.74 Mn | 73.61 Mn | - | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,000.00 |
| Dec 31, 2025 | -2.14 Mn |
| Sep 30, 2025 | 534,000.00 |
| Jun 30, 2025 | 744,000.00 |
| Mar 31, 2025 | 865,000.00 |
| Dec 31, 2024 | -3.61 Mn |
| Sep 30, 2024 | -26,000.00 |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | -14,000.00 |
| Dec 31, 2023 | 1.05 Mn |
| Sep 30, 2023 | -10,000.00 |
| Jun 30, 2023 | 976,000.00 |
| Mar 31, 2023 | -2,000.00 |
| Dec 31, 2022 | -9,000.00 |
| Sep 30, 2022 | 159,000.00 |
| Jun 30, 2022 | -2.60 Mn |
| Mar 31, 2022 | -13,000.00 |
| Dec 31, 2021 | -78,000.00 |
| Sep 30, 2021 | 3,000.00 |
| Jun 30, 2021 | -30,000.00 |